{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:36:12Z","timestamp":1787960172253,"version":"build-2784847793"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.ijcard.2006.06.003","type":"journal-article","created":{"date-parts":[[2006,8,7]],"date-time":"2006-08-07T10:36:57Z","timestamp":1154947017000},"page":"64-74","source":"Crossref","is-referenced-by-count":28,"title":["The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: A pooled analysis of double-blind, randomized trials"],"prefix":"10.1016","volume":"117","author":[{"given":"Hallvard","family":"Holdaas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Abletshauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gimpelewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Isaacsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2006.06.003_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0272-6386(98)70145-3","article-title":"Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease","volume":"32","author":"Levey","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijcard.2006.06.003_bib2","unstructured":"National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System, USRDS 1998 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1998."},{"key":"10.1016\/j.ijcard.2006.06.003_bib3","doi-asserted-by":"crossref","first-page":"c107","DOI":"10.1159\/000074835","article-title":"Therapeutic considerations for the use of statin therapy in chronic renal disease","volume":"95","author":"Moore","year":"2003","journal-title":"Nephron, Clin Pract"},{"key":"10.1016\/j.ijcard.2006.06.003_bib4","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.06.003_bib5","first-page":"263","article-title":"Assessment of the efficiency of treatment of dyslipidaemia in renal outpatients","volume":"15","author":"Harris","year":"2002","journal-title":"J Nephrol"},{"issue":"5 Suppl 3","key":"10.1016\/j.ijcard.2006.06.003_bib6","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1053\/ajkd.1998.v32.pm9820472","article-title":"Hyperlipidemia in patients with chronic renal disease","volume":"32","author":"Kasiske","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijcard.2006.06.003_bib7","first-page":"3","article-title":"Dyslipidemia and renal disease\u2014pathophysiology and lipid lowering therapy in patients with impaired renal function","volume":"3","author":"Lechleitner","year":"2000","journal-title":"J Clin Basic Cardiol"},{"key":"10.1016\/j.ijcard.2006.06.003_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2003.09.012","article-title":"The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease","volume":"43","author":"Fathi","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijcard.2006.06.003_bib9","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labeling. May 1998."},{"key":"10.1016\/j.ijcard.2006.06.003_bib10","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2006.06.003_bib11","doi-asserted-by":"crossref","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7\u201322.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"10.1016\/j.ijcard.2006.06.003_bib12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2006.06.003_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-138-2-200301210-00010","article-title":"Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency","volume":"138","author":"Tonelli","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijcard.2006.06.003_bib14","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.06.003_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752730600502X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752730600502X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T10:44:35Z","timestamp":1555757075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752730600502X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S016752730600502X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2006.06.003","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}